story of the week
Effect of Nonmyeloablative HSCT vs Continued Disease-Modifying Therapy on Disease Progression in Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
JAMA 2019 Jan 15;321(2)165-174, RK Burt, R Balabanov, J Burman, B Sharrack, JA Snowden, MC Oliveira, J Fagius, J Rose, F Nelson, AA Barreira, K Carlson, X Han, D Moraes, A Morgan, K Quigley, K Yaung, R Buckley, C Alldredge, A Clendenan, MA Calvario, J Henry, B Jovanovic, IB HelenowskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.